Tag: plus royalties. Glaxo said on Friday that Novartis will own rights to ofatumumab

Corporate

GLAXO SMITHKLINE SELLS RIGHTS TO NOVARTIS AG OF DRUG USED IN TREATING AUTOIMMUNE DISEASES

sarkarimirror

LONDON—  GlaxoSmithKline PLC is selling its remaining rights to a drug for use in treating autoimmune diseases, including multiple sclerosis, to Novartis  AG for up to $1 billion, plus royalties. Glaxo … Read More